The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile

CNS Drug Reviews

Volumn 10, Issue 1, 2004, Pages 23-44

  Hajós, Mihály ^a,c   Fleishaker, Joseph C ^a   Filipiak Reisner, Jacqueline K ^a   Brown, Mark T ^a   Wong, Erik H F ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Pfizer Inc ^*

^c PFIZER INC   (United States)

Author keywords

Antidepressants; Depression; Norepinephrine; Reboxetine; Transporter

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; IDAZOXAN; IMIPRAMINE; MESYLIC ACID; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PIPEROXAN; PLACEBO; REBOXETINE; SEROTONIN TRANSPORTER; TRICYCLIC ANTIDEPRESSANT AGENT; VILOXAZINE;

ANOREXIA; ANTICHOLINERGIC EFFECT; ASTHENIA; BLOOD PRESSURE; BRAIN FUNCTION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITION; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTHYMIA; EJACULATION DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; IC 50; IMPOTENCE; INSOMNIA; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QT INTERVAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TACHYCARDIA; URINARY HESITANCY; URINE RETENTION; XEROSTOMIA;

EID: 1642293910     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2004.tb00002.x     Document Type: Review

References (135)

1. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-399.
2. Aston-Jones G, Rajkowski J, Cohen J. Role of locus coeruleus in attention and behavioral flexibility. Biol Psychiatry 1999;46:1309-1320.
3. Avenoso A, Facciolȧ G, Scordo MG, et al. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Monit 1999;2:577-579.
4. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: A comparative study with desipramine, with methodologic considerations. Hum Psychopharmacol 1998;13:S29-S39.
5. Benmansour S, Cecchi M, Morilak DA, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999;19:10494-10501.
6. Berridge CW: Modulation of forebrain electroencephalographic activity and behavioral state by the locus coeruleus-noradrenergic system: Involvement of the medial septal area. Adv Pharmacol 1998;42:744-748.
7. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7(Suppl 1):S37-S47.
8. Beyer CE, Boikess S, Luo B, Dawson LA. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: An in vivo microdialysis study. J Psychopharmacol 2002;16:297-304.
9. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029.
10. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 1988;94:147-160.
11. Bragin A, Jando G, Nadasdy Z, Hetke J, Wise K, Buzsáki G. Gamma frequency (40-100 Hz) patterns in the hippocampus of the behaving rat. J Neurosci 1995;15:47-60.
12. Brown RE, Sergeeva OA, Eriksson KS, Haas HL. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci 2002;22: 8850-8859.
13. Brunello N, Mendlewicz J, Kasper S, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002;12:461-475.
14. Buzsaki G. Theta oscillations in the hippocampus. Neuron 2002;33:325-340.
15. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
16. Carra S, Blom J, Tascedda F, Brunello N, Labbe M, Barden N. Region-specific BDNF expression modulation by chronic antidepressant treatment in a transgenic mouse model of depression. Soc Neurosci Abstr 2001;27:Program No. 564.7.
17. Chen B, Dowlatshahi D, MacQueen GM, Wang J, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260-265.
18. Chergui K, Charlety PJ, Akaoka H, et al. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 1993;5:137-144.
19. Cocchiara G, Battaglia R, Pevarello P, et al. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 1991; 16:231-239.
20. Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE. Reboxetine attenuates forced swim test-induced behavioral and neurochemical alterations in the rat. Eur J Pharmacol 1999;379:125-133.
21. Coulomb F, Ducret F, Fiorentini F, et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000;40:482-487.
22. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA. Use of dopamine-β-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 2001;298:651-657.
23. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: An open label study. Hum Psychopharmacol 2002;17:329-333.
24. Davies DS, Murray S, Edwards RJ, et al. Inhibitory potential of reboxetine on major drug metabolizing forms of P450 in humans [abstract]. American College of Neuropsychopharmacology 36th Annual Meeting, 1997, December 8-12; Waikoloa (Hawaii).
25. Dekeyne A, Gobert A, Auclair A, Girardon S, Millan MJ. Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors. Psychopharmacology (Berl) 2002;162:156-167.
26. Denolle T, Pellizzoni C, Jannuzzo MG, et al. Hemodynamic effects of reboxetine in healthy male volunteers. Clin Phalmacol Ther 1999;66:282-287.
27. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999;46:212-220.
28. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry 2000;61 (Suppl 1):5-12.
29. Delgado PL, Moreno FA, Onate L, Gelenberg AJ. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 2002;5:63-66.
30. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharm 1997;7(Suppl 1):S49-S55.
31. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11(4,Suppl):S17-S23.
32. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
33. Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Disp 1995;16:443-460.
34. El-Giamal N, de Zwaan M, Bailer U, et al. Reboxetine in the treatment of bulimia nervosa: A report of seven cases. Int Clin Psychopharmacol 2000;15:351-356.
35. Ferguson JM, Mendels J, Schwartz GE: Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression. Clin Psychopharmacol. 2002;17:45-51.
36. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: Effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9-14.
37. Fiorentini F, Poggesi I, Januzzo MG, et al. Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers [abstract]. Eur Neuropsychopharmacol 1995;5:300.
38. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001;70:261-269.
39. Fleishaker JC, Herman BD, Pearson LK, et al. Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clin Drug Invest 1999;18:141-150.
40. Fleishaker JC, Mucci M, Pellizzoni C, et al. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Disp 1999;20:53-57.
41. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry 2002; 7(Suppl 1):S23-S28.
42. Frazer A. Norepinephrine involvement in antidepressant action. J Clin Psychiatry 2000;61(Suppl 10):25-30.
43. Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry 1999;46:1243-1252.
44. Garcia R. Stress, synaptic plasticity, and psychopathology. Rev Neurosci 2002;13(3):195-208.
45. 1A receptor antagonist and an SSRl in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995;115:1064-1070.
46. Grant MM, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol Psychiatry 2001;49:117-129.
47. Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect 1993;93:11-25.
48. Gross DW, Gotman J. Correlation of high-frequency oscillations with the sleep-wake cycle and cognitive activity in humans. Neuroscience 1999;94:1005-1018.
49. Hajós M, Gartside SE, Sharp T. Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn Schmiedeberg's Arch Pharmacol 1995;351: 624-629.
50. Hajós M, Hoffmann WE, Robinson DD, Yu JH, Hajós-Korcsok É. Norepinephrine but not serotonin reuptake inhibitors enhance theta and gamma activity of the septo-hippocampal system. Neuropsychopharmacology 2003;28:857-864.
51. Hajós-Korcsok É, McTavish SF, Sharp T. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: Microdialysis studies using paroxetine. Eur J Pharmacol 2000;407: 101-107.
52. Hajós-Korcsok É, Robinson DD, Yu JH, Fitch CS, Walker E, Merchant KM. Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeated footshock stress in rats. Pharmacol Biochem Behav 2003;1974:609-616.
53. Harkin A, Kelly JP, McNamara M, et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999;364:123-132.
54. 1-adrenergic receptors in an animal model of depression. J Neural Trasm 2000;107:1213-1227.
55. Hendershot PE, Fleishaker JC, Lin KM, Nuccio ID, Poland RE. Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. Psychopharmacology 2001;155:148-153.
56. Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the anti-depressant reboxetine in humans. Clin Pharmacol Ther 1999;66:374-379.
57. Herman JP, Renda A, Bodie B. Norepinephrine-γ-aminobutyric acid (GABA) interaction in limbic stress circuits: Effects of reboxetine on GABAergic neurons. Biol Psychiatry 2003;53(2):166-174.
58. Hilger E, Willeit M, Praschak-Rieder N, Stastny J, Neumeister A, Kasper S. Reboxetine in seasonal affective disorder: An open trial. Eur Neuropsychopharmacol 2001;11:1-5.
59. Hindmarch I. Effect of antidepressants on cognitive and psychomotor function: The lack of effect of reboxetine. Hum Psychopharmacol 1998;13:S21-S27.
60. 2-adrenoceptors in the prefrontal cortex. Br J Pharmacol 2001;132:183-188.
61. Jacobs BL, Fomal CA. Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 1999;21(2 Suppl):9S-15S.
62. Jensen O, Tesche CD (2002): Frontal theta activity in humans increases with memory load in a working memory task. Eur J Neurosci 15:1395-1399.
63. Jannuzzo MG, Ryde M, Karlmark B, et al. Pharmacokinetics of reboxetine in healthy volunteers of different ages [abstract]. Eur Neuropsychopharmacol 1995;5:300.
64. Jannuzzo MG, Strolin Benedetti M, Duchene P, et al. Pharmacokinetics of reboxetine in the elderly [abstract]. Advances in simultaneous pharmacokinetic/pharmacodynamic modeling. 2nd International symposium. Measurement and kinetics of in vivo drug effects. Noorwijkerhout, The Netherlands, 14-16 April, 1994. Book of abstracts; 94-96.
65. Januzzo MG, Bosc M, Renoux A, et al. Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers [abstract]. Eur Neuropsychopharmacol 1995;5:300-301.
66. Jolly DC, Richards JB, Seiden LS. Serotonergic mediation of DRL 72s behavior: Receptor subtype involvement in a behavioral screen for antidepressant drugs. Biol Psychiatry 1999;45:1151-1162.
67. Kasper S, el Giamal N, Hilger E. Reboxetine: The first selective noradrenaline reuptake inhibitor. Exp Opin Pharmacother 2000;1:771-782.
68. Katona C, Bercoff E, Chiu E, Tack P, Versiani V, Woelk H. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomized trial. J Affect Dis 1999;55:203-213.
69. Keller M. Role of serotonin and noradrenaline in social dysfunction: A review of data on reboxetine and the Social Adaptation Self-Evaluation Scale (SASS). Gen Hosp Psychiatry 2001;23:15-19.
70. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003;28:413-420.
71. Lam Y, Ereshefsky L, Toney G, et al. The effects of reboxetine and nefazodone on the pharmacokinetics and pharmacodynamics of alprazolam. Annual Meeting of the American Psychiatric Association. Chicago, IL, USA, May 2000;13-18.
72. Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: A pilot study. Sleep 2001;24:282-285.
73. Lee AL, Ogle WO, Sapolsky RM. Stress and depression: Possible links to neuron death in the hippocampus. Bipolar Disord 2002;4:117-128.
74. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63: 300-304.
75. Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 2001;297:540-546.
76. 2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2002;27:691-698.
77. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;20:9104-9110.
78. Massana J, Moller HJ. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.
79. 2-adrenoceptors regulating noradrenergic transmission in the rat brain: A dual-probe microdialysis study. Br J Pharmacol 2001;133:1362-1370.
80. Meyer TE, Habener JF. Cyclic adenosine 3′,5′-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocrinol Rev 1993;14: 269-290.
81. Millan MJ, Gobert A, Lejeune F, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001;298:565-580.
82. Millan MJ, Dekeyne A, Papp M, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001;298:581-591.
83. Miller DK, Wong EH, Chesnut MD, Dwoskin LP. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2002;302:687-695.
84. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996;53:117-128.
85. Montminy M. Transcriptional regulation by cyclic AMP. Annu Rev Biochem 1997;66:807-822.
86. Mucci M. Reboxetine: A review of antidepressant tolerability. J Psychopharmacology 1997;11(Suppl 4): S33-S37.
87. Nestler EJ, Alreja M, Aghajanian GK. Molecular control of locus coeruleus neurotransmission. Biol Psychiatry 1999;46:1131-1139.
88. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
89. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments, J Neurosci 1995;15:7539-7547.
90. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-2372.
91. Nyback HV, Walters JR, Aghajanian GK, Roth RH. Tricyclic antidepressants: Effects on the firing rate of brain noradrenergic neurons. Eur J Pharmacol 1975;32:302-312.
92. O'Donnell JM, Seiden LS. Differential-reinforcement-of-low-rate 72-second schedule: Selective effects of antidepressant drugs. J Pharmacol Exp Ther 1983;224:80-88.
93. Page ME, Lucki I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 2002;27:237-247.
94. Page ME, Brown K, Lucki I. Simultaneous analyses of the neurochemical and behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of antidepressant action. Psychopharmacology 2003;165:194-201.
95. Parker G. "New" and "old" antidepressants: All equal in the eyes of the lore? Br J Psychiatry 2001;179: 95-96.
96. Pellizzoni C, Poggesi I, Jorgensen NP, et al. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Disp 1996;17:623-633.
97. Pellizzoni C, Strolin Benedetti M, Poggesi I, et al. Pharmacokinetics of reboxetine in healthy volunteers: Relative bioavailability and food effect [abstract]. Pharmacol Res 1995;31(Suppl):41.
98. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001;21:6706-6717.
99. Poggesi I, Pellizzoni C, Fleishaker JC. Pharmacokinetics of reboxetine in elderly patients with depressive disorders. Int J Clin Pharmacol Ther 2000;38:254-259.
100. Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: Their functional role and the action of antidepressant drugs. J Neurochem 2000;74:21-33.
101. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R. Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 1994;63: 195-200.
102. Raghavachari S, Kahana MJ, Rizzuto DS, et al. Gating of human theta oscillations by a working memory task. J Neurosci 2001;21:3175-3183.
103. Rammsayer TH, Hennig J, Haag A, Lange N: Effects of noradrenergic activity on temporal information processing in humans. Quart J Exp Psychol B 2001;54:247-258.
104. Reneric JP, Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998;136:190-197.
105. Reuster T, Buechler J, Winiecki P, Oehler J. Influence of reboxetine on salivary MHPG concentration and cognitive symptoms among patients with alcohol-related Korsakoff's syndrome. Neuropsychopharmacology 2003:28:974-978.
106. Rey E, Dostert P, d'Athis Ph. et al. Dose proportionality of reboxetine enantiomers in healthy volunteers. Biopharm Drug Disp 1999;20:177-181.
107. Riva M, Brunello N, Rovescalli AC, et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies. J Drug Dev 1989;1:243-253.
108. Rocchetti M, Pellizzoni C, Poggesi I, et al. Genetic polymorphism and reboxetine metabolism [abstract 80]. 1st Congress of the European Association for Clinical Pharmacology and Therapeutics. Therapie 1995 (Suppl), Abstract 80.
109. Rogoz Z, Wrobel A, Krasicka-Domka M, Maj J, Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely. Pol J Pharmacol 1999;51:399-404.
110. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by anti-depressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003;23: 349-357.
111. Sacchetti G, Bernini M, Bianchetti A, Parini S, Invemizzi RW, Samanin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br J Pharmacol 1999;128:1332-1338.
112. 2-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 2001;363:66-72.
113. Salomon RM, Miller HL, Delgado PL, Charney D. The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. Int Clin Psychopharmacol 1993; 8(Suppl 2):41-46.
114. Siepmann M, Muck-Weymann M, Joraschky P, Kirch W. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2001;157:202-207.
115. Smith SL, Wu H, Merchant KM. The norepinephrine transporter selective antidepressant, reboxetine, blocks stress-induced neuroendocrine and genomic responses [abstract]. Annual Meeting of American College of Neuropsychopharmacology, 1999.
116. 1A receptor activation: An electrophysiological and neurochemical study in guinea pig dorsal raphe and hippocampus. Ann NY Acad Sci 1998;861:272-273.
117. Steru L, Chermat R, Thierry B, et al. The automated Tail Suspension Test: A computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:659-671.
118. Svensson TH, Usdin T. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: Alpha-receptor mediation. Science 1978;202:1089-1091.
119. Szabadi E, Bradshaw CM, Boston PF, Langley RW. The human pharmacology of reboxetine. Hum Psychopharmacology Clin Exp 1998;13:S3-S12.
120. Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 2001;13:2077-2087.
121. Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000;3:1-11.
122. Tanum L. Reboxetine: Tolerability and safety profile in patients with major depression. Acta Psychiatr Scand 2000;402(Suppl):37-40.
123. Thomas DN, Holman RB. A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J Neurochem 1991;56:1741-1746.
124. Tran A, Laneury JP, Duchene P, et al. Pharmacokinetics of reboxetine in volunteers with hepatic impairment. Clin Drug Invest 2000;19:473-477.
125. Usher M, Cohen JD, Servan-Schreiber D, Rajkowski J, Aston-Jones G. The role of locus coeruleus in the regulation of cognitive performance. Science 1999;283:549-554.
126. Valentino RJ, Curtis AL, Page ME, Pavcovich LA, Florin-Lechner SM. Activation of the locus coeruleus brain noradrenergic system during stress: Circuitry, consequences, and regulation. Adv Pharmacol 1998:42:781-784.
127. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31-37.
128. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in patients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34.
129. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999;60: 400-406.
130. Vertes RP, Kocsis B: Brainstem-diencephalo-septohippocampal systems controlling the theta rhythm of the hippocampus. Neuroscience 1997;81:893-926.
131. Von Voigtlander PF, Triezenberg HJ, Losey EG. Interactions between clonidine and antidepressant drugs: A method for identifying antidepressant-like agents. Neuropharmacology 1978;17:375-381.
132. Wienkers LC, Allievi C, Hauer MJ, et al. Cytochrome P450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Disp 1999;27: 1334-1340.
133. Wong EH, Sonders MS, Amara SG, et al. Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000;47:818-829.
134. Wong EHF, Tinholt T, McFinton P, Cortes-Burgos L, Amara S, Sonders M. Novel enantiomeric selectivity of reboxetine at the catecholamine transporters [abstact]. Soc Neurosci 2001;975.16.
135. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998;71:274-280.